Oncology Biopharma TESARO (TSRO) Files $86.25M IPO
Tweet
Share
E-mailGet Alerts TSRO Hot Sheet
Join SI Premium – FREE
TESARO, Inc. (Nasdaq: TSRO), filed a registration with the U.S. Securities and Exchange Commission for an Initial Public Offering of its Common Stock. The proposed maximum offering price is $86.25 million. TESARO plans to list on the Nasdaq Global Market under the ticker "TSRO."
The offering is being made through Citigroup, Morgan Stanley, Leerink Swann, BMO Capital Markets, and Baird.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.
The offering is being made through Citigroup, Morgan Stanley, Leerink Swann, BMO Capital Markets, and Baird.
TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients.
Create E-mail Alert Related Categories
IPOsRelated Entities
Citi, Morgan Stanley, Robert W Baird, BMO CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
